In a filing, Surgery Partners Inc revealed its National Group President Bane Harrison R. unloaded Company’s shares for reported $1.44 million on Feb 07 ’25. In the deal valued at $25.64 per share,56,315 shares were sold. As a result of this transaction, Bane Harrison R. now holds 107,037 shares worth roughly $2.72 million.
Then, Doherty David T sold 13,641 shares, generating $349,346 in total proceeds. Upon selling the shares at $25.61, the Chief Financial Officer now owns 108,862 shares.
Before that, Brittenham Marissa sold 14,700 shares. Surgery Partners Inc shares valued at $376,467 were divested by the Chief Strategy Officer at a price of $25.61 per share. As a result of the transaction, Brittenham Marissa now holds 50,178 shares, worth roughly $1.28 million.
BofA Securities initiated its Surgery Partners Inc [SGRY] rating to a Buy in a research note published on December 16, 2024; the price target was $30. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering SGRY with “Sector weight” recommendation on October 11, 2024. Macquarie started covering the stock on June 28, 2024. It rated SGRY as “an Outperform”.
Price Performance Review of SGRY
On Tuesday, Surgery Partners Inc [NASDAQ:SGRY] saw its stock jump 1.11% to $25.44. Over the last five days, the stock has lost -1.59%. Surgery Partners Inc shares have risen nearly 20.17% since the year began. Nevertheless, the stocks have fallen -22.58% over the past one year. While a 52-week high of $34.10 was reached on 02/14/25, a 52-week low of $19.50 was recorded on 01/14/25. SMA at 50 days reached $22.67, while 200 days put it at $26.66.
Levels Of Support And Resistance For SGRY Stock
The 24-hour chart illustrates a support level at 25.14, which if violated will result in even more drops to 24.84. On the upside, there is a resistance level at 25.62. A further resistance level may holdings at 25.80. The Relative Strength Index (RSI) on the 14-day chart is 60.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.16%. Stochastics %K at 16.75% indicates the stock is a buying.
The most recent change occurred on March 06, 2024 when Barclays began covering the stock and recommended ‘”an Equal weight”‘ rating along with a $35 price target.
